Compare Novartis AG (NVS) vs S&P Global Inc (SPGI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs S&P Global Inc — how do they compare? Novartis AG trades at $142.74 (market cap $268.57B), while S&P Global Inc trades at $403.72 (market cap $118.72B). The key difference: Novartis AG is far larger — about 2.3× S&P Global Inc's market cap, and Novartis AG pays the higher dividend (3.31%). Which is the better fit depends on your goals — on Pluang, investors hold Novartis AG for 82 Days and S&P Global Inc for 123 Days on average.
| NVS | SPGI | |
|---|---|---|
Market Cap | $268.57B | $118.72B |
Volume | 1,532,573 | 1,647,917 |
Sector | Health | Financials |
52-Week High | $168.62 | $517.92 |
52-Week Low | $121.80 | $370.42 |
Typical Hold Time | 82 Days | 123 Days |
Enterprise Value | $309.89B | $130.21B |
Dividend Yield | 3.31% | 0.96% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novartis (NVS) trades at $143.28, up 1.77% today, with mixed technical signals showing neutral momentum. The company demonstrates strong fundamentals with $56.67B revenue in 2025, 22.5% net margin, and consistent earnings beats in recent quarters. Recent developments include a significant $7.8B licensing deal with China's Abogen for mRNA therapy, though offset by clinical trial setbacks in ALS drug development and ongoing investor scrutiny of M&A strategy.
Outlook remains cautiously optimistic with analyst consensus target of $146 suggesting modest upside. Key opportunities include pipeline expansion through strategic partnerships, while risks involve clinical trial failures, M&A integration challenges, and patent cliff pressures. The stock presents a balanced risk-reward profile with strong profitability offset by pipeline execution concerns.
S&P Global (SPGI) trades at $395.18, down 0.24% on the day, with strong analyst support showing 85.7% buy ratings and a $509.50 consensus price target. The stock shows bearish technical signals but maintains robust fundamentals with 30.5% net margins and consistent revenue growth from $15.3B in 2025 to projected $16.1B in 2026. Recent developments include expansion into digital asset risk assessment and AI-driven growth initiatives.
The outlook remains positive given the company's dominant market position and financial strength, though technical weakness and high valuation multiples present near-term risks. Long-term growth drivers include AI integration and strategic acquisitions, while risks include market sensitivity to economic cycles and competitive pressures in financial services.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About S&P Global Inc
S&P Global provides data and benchmarks to capital and commodity market participants. In 2021 and excluding IHS Markit, S&P Ratings was over 45% of the firm's revenue and over 55% of the firm's operating income. S&P Ratings is the largest credit rating agency in the world. The firm's other segments include Market Intelligence, Indices, and Platts. Market Intelligence provides desktop tools and other data solutions to investment banks, corporations, and other entities. Indices provides benchmarks for financial markets and is monetized through subscriptions, asset-based fees, and transaction-based royalties. Platts provides benchmarks to commodity markets, principally petroleum.
Read more on SPGI →
